Digest Network Come funziona
Network
/
Società
Al
Non verificato

Alkermes plc

Di cosa scriviamo

BiotecnologiaFarmaceuticaPsichiatriaSaluteSanità

61 comunicati stampa

Guarda tutti i comunicati
20/10/2026
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alkermes to Report Third Quarter Financial Results on November 3, 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
13/10/2026
Eventi
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
21/09/2026
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
16/09/2026
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
10/09/2026
Multimedialità
Eventi
Appalti e gare
Industria
Psichiatria
Salute
Scienza
Farmaceutica
Biotecnologia
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
24/08/2026
Industria
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
The Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
28/07/2026
Web e Social Network
Telefonia e Varie
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Sanità
Salute
Psichiatria
Alkermes plc Reports Second Quarter 2026 Financial Results
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
14/07/2026
Biotecnologia
Sanità
Psichiatria
Salute
Farmaceutica
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Alkermes to Report Second Quarter Financial Results on July 28, 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
13/07/2026
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0
17/06/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Fonte
Alkermes plc
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0